Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

An updated UK real-world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 1565.

https://doi.org/10.1182/blood-2025-1565

Published: 2025

Journal Articles

Incorporation of 8Gy total body irradiation into reduced intensity conditioning does not improve allogeneic transplant outcomes for high-risk adult acute lymphoblastic leukemia: Results from the randomised prospective phase 2 UK multicentre ALL-RIC impact study

Blood (2025) 146 (Supplement 1): 374.

https://doi.org/10.1182/blood-2025-374

Published: 2025

Journal Articles

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

Blood (2025) 146 (Supplement 1): 3345.

https://doi.org/10.1182/blood-2025-3345

Published: 2025

Journal Articles

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

Blood (2025) 146 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2025-2369

Published: 2025

Journal Articles

The MEK Inhibitor Selumetinib in Combination with Dexamethasone Leads to Responses in Adult and Pediatric Patients with Relapsed RAS-Pathway Mutated Acute Lymphoblastic Leukemia: Results of a Phase 1/2 Study

Britta Julia Vormoor, Tobias Menne, Joshua Savage, Amit Patel, Anna Castleton, Adele Kay Fielding, Donna Lancaster, Anne Louise Latif, Nick Morley, Geoff Shenton, Gareth Veal, Julie Irving, Pam Kearns, Lucinda Billingham, Josef Vormoor

Blood (2023) 142 (Supplement 1): 2874.

https://doi.org/10.1182/blood-2023-185855

Published: 2023

Journal Articles

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 3268–3270.

https://doi.org/10.1182/blood-2022-162565

Published: 2022

Journal Articles

Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure

Blood (2022) 140 (Supplement 1): 2408–2410.

https://doi.org/10.1182/blood-2022-162863

Published: 2022

Journal Articles

Use of Cryopreserved Allogeneic PBSC Results in Delayed Engraftment and Increased Incidence of Poor Graft Function

Samar Kulkarni, John Murray, James Clarke, Mike Dennis, Amit Patel, Anna Castleton, James Cavet, Angela Leather, Lyndsey Ashton, Diane Sweeney, Joanna Tomlins, Adrian Bloor, Rita Angelica, Mark Williams

Blood (2021) 138 (Supplement 1): 1778.

https://doi.org/10.1182/blood-2021-154199

Published: 2021

Journal Articles

Second Malignant Neoplasms (SMN) in Myeloma Patients Post Stem Cell Transplant (SCT)

Samar Kulkarni, John Murray, Jim Cavet, Mike Dennis, Adrian Bloor, Amit Patel, Anna Castleton, Joanna Tomlins

Blood (2021) 138 (Supplement 1): 1839.

https://doi.org/10.1182/blood-2021-154366

Published: 2021

Journal Articles

Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-138438

Published: 2020

Journal Articles

Post Allograft Rituximab Responsive Cytopenia (RRC)

Samar Kulkarni, MD, John Murray, RGN, MSc, David Kaye, MSc, Michael Dennis, FRCPath, Anna Castleton, FRCPath, Mohd K Mamat, MRCP, James Cavet, Daniel Wiseman, FRCPath, Tim Somervaille, FRCPath, Sven Sommerfeld, MRCP, Richard Chasty, FRCPath, Adrian Bloor, FRCPath

Blood (2019) 134 (Supplement_1): 5645.

https://doi.org/10.1182/blood-2019-132214

Published: 2019

Journal Articles

Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity

Anna Castleton, Aditi Dey, Brendan Beaton, Bella Patel, Anne Aucher, Daniel M. Davis, Adele K. Fielding

Blood (2014) 123 (9): 1327–1335.

https://doi.org/10.1182/blood-2013-09-528851

Published: 2014

Includes: Multimedia, Supplemental data

Journal Articles

Donor Derived Acute Myeloid Leukaemia Following Allogeneic Cord Blood Transplantation: A Potential Role for RUNX1 and Down Syndrome Critical Region (DSCR) Genes.

Anna Castleton, Anastasios Chanalaris, Julie Howard-Reeves, Diana Brazma, Julie Glanville, Dean Nizetic, Ronjon Chakraverty, Elisabeth Nacheva

Blood (2009) 114 (22): 4300.

https://doi.org/10.1182/blood.V114.22.4300.4300

Published: 2009

Journal Articles

Female Gonadal Function Following Reduced Intensity Conditioning (RIC) Allogeneic Bone Marrow Transplantation for Haematological Malignancies.

Chara Kyriakou, MD, Melanie Davies, MD, Ratna Chatterjee, MD, PhD, Anna Castleton, MD, Kim Roberts, Andy Peniket, MD,PhD, Stephen Mackinnon, MD, Panagiotis D. Kottaridis, MD,PhD

Blood (2006) 108 (11): 3372.

https://doi.org/10.1182/blood.V108.11.3372.3372

Published: 2006

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

An updated UK real-world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia

Incorporation of 8Gy total body irradiation into reduced intensity conditioning does not improve allogeneic transplant outcomes for high-risk adult acute lymphoblastic leukemia: Results from the randomised prospective phase 2 UK multicentre ALL-RIC impact study

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

The MEK Inhibitor Selumetinib in Combination with Dexamethasone Leads to Responses in Adult and Pediatric Patients with Relapsed RAS-Pathway Mutated Acute Lymphoblastic Leukemia: Results of a Phase 1/2 Study

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure

Use of Cryopreserved Allogeneic PBSC Results in Delayed Engraftment and Increased Incidence of Poor Graft Function

Second Malignant Neoplasms (SMN) in Myeloma Patients Post Stem Cell Transplant (SCT)

Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme

Post Allograft Rituximab Responsive Cytopenia (RRC)

Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity

Donor Derived Acute Myeloid Leukaemia Following Allogeneic Cord Blood Transplantation: A Potential Role for RUNX1 and Down Syndrome Critical Region (DSCR) Genes.

Female Gonadal Function Following Reduced Intensity Conditioning (RIC) Allogeneic Bone Marrow Transplantation for Haematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only